Evidence mapPaperPMID 37460458Full record

ArticleNutrition & diabetes2023

Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study.

Jan Gojda, Kateřina Koudelková, Anna Ouřadová, Alexander Lang, Magdaléna Krbcová, Alexandra Gvozdeva, Viktor Šebo, Lotte Slagmolen, Jana Potočková, Petr Tůma and 4 more

Abstract read
In one paragraph

Article in Nutrition & diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Pathological Sequelae of SARS-CoV-2: A Review for Clinicians.The Yale journal of biology and medicine · 2024
    Review
  5. Article
  6. The prognostic significance of insulin resistance in COVID-19: a review.Journal of diabetes and metabolic disorders · 2024
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jan GojdaDepartment of Internal Medicine, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic. jan.gojda@lf3.cuni.cz.ORCID 0000-0002-7995-5947
Kateřina KoudelkováDepartment of Internal Medicine, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.
Anna OuřadováDepartment of Internal Medicine, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.
Alexander LangInstitute for Biometrics and Epidemiology, German Diabetes Center (Deutsches Diabetes-Zentrum/DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-0584-3213
Magdaléna KrbcováDepartment of Internal Medicine, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.ORCID 0000-0001-7376-611X
Alexandra GvozdevaDepartment of Internal Medicine, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.
Viktor ŠeboDepartment of Pathophysiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Lotte SlagmolenFaculty of Movement and Rehabilitation Sciences, Katholieke Universiteit Leuven, Leuven, Belgium.
Jana PotočkováDepartment of Internal Medicine, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.
Petr TůmaDepartment of Hygiene, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Lenka RossmeislováInstitute for Biometrics and Epidemiology, German Diabetes Center (Deutsches Diabetes-Zentrum/DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Michal AndělDepartment of Internal Medicine, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.
Fredrik KarpeOxford Center for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK.ORCID 0000-0002-2751-1770
Sabrina SchlesingerGerman Center for Diabetes Research (DZD), Partner Düsseldorf, Düsseldorf, Germany.ORCID 0000-0003-4244-0832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or beta cell dysfunction. MATERIALS AND

methodsSurvivors of severe COVID-19 but without a known history of diabetes were examined at baseline (T0) and after 3 (T3) and 6 (T6) months: corticosteroids use, indirect calorimetry, and OGTT. Insulin response and sensitivity (IS) were expressed as insulinogenic (IGI), disposition (DI), and Matsuda insulin sensitivity index (ISI). Resting energy expenditure (REE) and respiratory quotient (RQ) was calculated from the gas exchange and nitrogen losses.

results26 patients (out of 37) with complete outcome data were included in the analysis (age ~59.0 years; BMI ~ 30.4, 35% women). Patients were hypermetabolic at T0 (30.3 ± 4.0 kcal/kg lean mass/day, ~120% predicted) but REE declined over 6 months (ΔT6-T0 mean dif. T6-T0 (95% CI): -5.4 (-6.8, -4.1) kcal/kg FFM/day, p < 0.0001). 17 patients at T0 and 13 patients at T6 had hyperglycemia. None of the patients had positive islet autoantibodies. Insulin sensitivity in T0 was similarly low in hyperglycemic (H) and normoglycemic patients (N) (T0 ISI

conclusionsPatients with severe COVID-19 had increased REE and insulin resistance during the acute phase due to the infection and corticosteroid use, but these effects do not persist during the follow-up period. Only patients with insufficient insulin response developed hyperglycemia, indicating that beta cell dysfunction, rather than insulin resistance, was responsible for its occurrence.

Indexed as

COVID-19HyperglycemiaInsulin ResistanceBlood GlucoseFemaleHumansInsulinMaleMiddle AgedProspective StudiesSARS-CoV-2Blood GlucoseInsulin

Identifiers

PMID37460458
PMCPMC10352285

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.